Automated Inpatient Continuous Blood Glucose Monitoring IP

The Company is refining an electrochemistry-based automated blood glucose monitoring technology for use in hospital general ward populations. Between 25-40% of total admissions, both diabetics and non-diabetics, in these wards experience blood sugar complications (glycemic complications). More than 30 million patients are admitted to regular hospital beds in the U.S. annually. The rapidly growing global market for inpatient blood glucose monitoring technologies is approaching $5B worldwide. The U.S. accounts for 40% of this market, which is demanding innovative technologies for lowering costs and improving patient outcomes. 

The automated cCGMS provides a more accurate, reliable, and real-time blood glucose monitoring system at the patient’s bedside. The fundamental measurement technology already demonstrated accuracy meeting and exceeding current regulatory specifications in human studies. Our cost effective solution will empower healthcare providers with accurate and timely data for more appropriate blood sugar management. The benefits of improved management and control include reducing infections and intensive care utilization by as much as 50% and cost savings in the billions of dollars annually.